Braveheart Bio (NASDAQ:BRVE) Director David Malek Acquires 4,166 Shares

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Malek bought 4,166 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $74,988.00. Following the completion of the acquisition, the director directly owned 533,845 shares in the company, valued at $9,609,210. The trade was a 0.79% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Braveheart Bio Stock Performance

Shares of Braveheart Bio stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a 1 year low of $28.47 and a 1 year high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.